Multiple Myeloma Clinical Trial

UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies

Summary

The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with advanced hematological malignancies who have failed at least two lines of therapy.
Karnofsky performance score > 60, unless due to disease and then > 50.
Age > 18 years.
An expected survival of > 3 months.
Subjects must have signed an IRB-approved consent and been informed about the investigational nature of the study.
Cord blood must have negative serology for HIV.
Release of cord blood.
The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient body weight.

Exclusion Criteria:

Liver function: total bilirubin > 2x ULN or AST/ALT > 3x ULN.
Creatinine > 3.0 mg/dL.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Study ID:

NCT00578045

Recruitment Status:

Withdrawn

Sponsor:

University of Arkansas

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Arkansas for Medical Sciences
Little Rock Arkansas, 72205, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Study ID:

NCT00578045

Recruitment Status:

Withdrawn

Sponsor:


University of Arkansas

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider